



URGENT: DRUG RECALL

Important Note: This recall letter is being re-issued following reclassification from Class III to Class II by the U.S. Food and Drug Administration. Please notify your customers accordingly. If you may have further distributed this product, please identify your customers and notify them at once of this product recall. Your notification to your customers may be enhanced by including a copy of this recall notification letter.

Dear Customer:

June 16, 2026

This is to inform you of a product recall involving Minocycline Hydrochloride Extended-Release (ER) Tablets USP, 115 mg. Please reference lot-specific information included below.

	Product Name	Lot Number	Strength	Expiration Date	Pack Size	NDC	Initial Distribution Date	Quantity Distributed (in bottles)
1	Minocycline Hydrochloride Extended-Release Tablets USP, 115 mg	25141635	115 mg	April 30, 2028	30 tablets/bottle	67877-644-30	September 5, 2025	360 bottles

See enclosed product labels for ease in identifying the product at the RETAIL level.

An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis for long-term stability testing (LT conditions: 25 ± 2 °C / 60 ± 5 % RH) of Minocycline Hydrochloride Extended-Release Tablets USP, 115 mg, for batch number 25141635.

Minocycline HCl ER tablets is a tetracycline class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. Further, the drug is not indicated for use in the last half of pregnancy, infancy and childhood up to the age of 8 years. Dissolution results up to 6 months are well within the specification limits. Results of Assay, CU and impurity testing are well within the specification limits. Hence, there risk to the patient with respect to safety of the medication is negligible.

Our firm began shipping this product on September 5, 2025. Immediately examine your inventory and quarantine product subject to recall for the lot number specified in the table above.

Please perform the following activities:

- Immediately examine your inventory and quarantine product subject to recall for the lot numbers specified in the table above. Please follow the directions in the attached recall stock response to return the affected product.
- Promptly complete the attached recall stock response form even if you have no product to return.
- The completed Recall Response Form can be submitted by any of the following methods:

Fax: 817-868-5362 or E-mail: rxrecalls@inmar.com

This recall is being carried out to the RETAIL level. Your assistance is appreciated and necessary to prevent consumer harm.



Your assistance is appreciated and necessary in this voluntary recall. If you have any questions related to customer service, please contact product inquiries—available 24 hours a day, 7 days a week—at 877-272-7901. If you have any questions about the return of the product, please contact Inmar toll free at 855-802-1469—available 9:00 AM to 5:00 PM ET Monday through Friday (excluding holidays).

This recall is being conducted with the knowledge of the Food and Drug Administration.

Sincerely,

A handwritten signature in blue ink, appearing to read "Hindy Schiff".

Hindy Schiff

Vice President, Regulatory Affairs and Compliance



RECALL STOCK RESPONSE FORM

Recall: Minocycline Hydrochloride Extended-Release Tablets USP, 115 mg

Lot Number: 25141635

Customer Name: _____ DEA #: _____

***Please note that DEA # is required. If it is not provided, the processing of your form will be delayed. ***

Address: _____

City: _____ State: _____ Zip Code: _____

Contact Name (please print): _____ Telephone #: _____

Contact Signature: _____ Date: _____

Wholesaler Information if not directly purchased from Ascend:

Wholesaler Name: _____ Wholesaler DEA#: _____

Wholesaler City: _____ Wholesaler State: _____ Wholesaler Zip: _____

Please check and fill out each section accordingly.

- I have read and understand the recall instructions provided in the Recall Letter.
- I have checked my stock for the quarantined inventory indicated in the table below.

	Product Name	Lot Number	Strength	Expiration Date	Pack Size	NDC	Quantity on Hand (in bottles)
1	Minocycline Hydrochloride Extended-Release Tablets USP, 115 mg	25141635	115 mg	April 30, 2028	30 tablets/ bottle	67877-644-30	
Total Product							

- Indicate disposition of recall product:
 - Returned/Held for Return (Yes / No)
 - Quantity: _____
 - Date: _____
 - Method: _____

OR

- No recall product on hand (Yes / No)



- I have identified and notified my customers that this product was shipped/received or may have been shipped by:
 - Date: _____
 - Method of Notification: _____

Were there any adverse events associated with the recalled product?

- Yes
- No

If yes, please explain: _____

If you have any questions regarding this form or product return, please contact Inmar at 1-855-802-1469. Office Hours: 9:00 AM to 5:00 PM EST Monday through Friday (excluding holidays).

Please return this form by fax to 1-817-868-5362 or E-mail rxrecalls@inmar.com.

After receipt of this response form, a return kit will be provided for affected product return to:

Inmar Rx Solutions
3845 Grand Lakes Way
Grand Prairie, TX, 75050

Inmar Recall Event ID: RCL138-26